Product
IBI343
2 clinical trials
2 indications
Indication
CarcinomaClinical trial
A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-05-31